Literature DB >> 29247952

Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.

Bai He1, Feng Yan1, Changping Wu2.   

Abstract

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) seriously threatens patients life with the morbidity increases at a high rate. Immune response disorder is the potential factor that induces DLBCL, while the potential mechanism still not fully understand.
METHODS: Real-time PCR and western blot were performed to determine genes expression. Flow cytometry was employed to detect the expression of PD-1 and the ratio of PD-1+T cells. Enzyme-linked immune sorbent assay (ELISA) was used to determine the cytokines secretion.
RESULTS: MiR-195 was down-regulated, while PD-L1 was up-regulated in DLBCL tissues, and the rate of PD-1+T cells was increased in T cells of peripheral blood in DLBCL. Overexpressed miR-195 suppressed the expression of PD-L1. Moreover, miR-195 overexpression significantly promoted the secretion of IFN-γ and TNF-α, but decreased IL-10 and PD-1+T cells rate in the co-culture model of T cells and OCI-Ly-10 cells. MiR-195 targets PD-L1 to regulate the expression of IFN-γ, TNF-α, IL-10 and the rate of PD-1+T cells.
CONCLUSION: MiR-195 regulated immune response of DLBCL through targeting PD-L1.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; Immune response; PD-L1; miR-195

Mesh:

Substances:

Year:  2017        PMID: 29247952     DOI: 10.1016/j.biopha.2017.11.146

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

Review 1.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors:  Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal:  Nat Rev Clin Oncol       Date:  2022-02-07       Impact factor: 66.675

2.  PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: with the involvement of the HDAC3/microRNA-195-5p/SGK1.

Authors:  Shu-Cheng Liu; Li-Bo Chen; Ping-Feng Chen; Meng-Long Huang; Tian-Pei Liu; Jun Peng; Xin-Sheng Lu
Journal:  Clin Epigenetics       Date:  2022-10-20       Impact factor: 7.259

3.  miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139.

Authors:  Hongfeng Nie; Jixing Mu; Jinsheng Wang; Yong Li
Journal:  Oncol Rep       Date:  2018-06-25       Impact factor: 3.906

Review 4.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

5.  MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.

Authors:  Jing-Ran Sun; Xiao Zhang; Ya Zhang
Journal:  Cell Mol Biol Lett       Date:  2019-12-04       Impact factor: 5.787

6.  Clinical Features and Prognostic Impact of Coexpression Modules Constructed by WGCNA for Diffuse Large B-Cell Lymphoma.

Authors:  Jianjun Xiao; Xuemei Wang; Haitao Bai
Journal:  Biomed Res Int       Date:  2020-06-07       Impact factor: 3.411

Review 7.  PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.

Authors:  Joshua W D Tobin; Karolina Bednarska; Ashlea Campbell; Colm Keane
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

Review 8.  Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.

Authors:  Rosemarie Tremblay-LeMay; Nasrin Rastgoo; Hong Chang
Journal:  J Hematol Oncol       Date:  2018-03-27       Impact factor: 17.388

Review 9.  The role of cancer-derived microRNAs in cancer immune escape.

Authors:  Ming Yi; Linping Xu; Ying Jiao; Suxia Luo; Anping Li; Kongming Wu
Journal:  J Hematol Oncol       Date:  2020-03-28       Impact factor: 17.388

10.  Proliferation and Apoptosis of B-Cell Lymphoma Cells under Targeted Regulation of FOXO3 by miR-155.

Authors:  Xiaoqiang Zheng; Hongbing Rui; Ying Liu; Jinfeng Dong
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-11-01       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.